Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,948 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: COVID-19 Pneumonia Clear all
Completed No phase listed Observational

Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California

NCT04848584
View directory record Official record
Conditions
COVID-19
Interventions
Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine, BNT162b2 BA.4/5 bivalent, XBB.1.5-adapted vaccinated
Biological
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 14, 2026, 1:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19

NCT04399252
View directory record Official record
Conditions
Microbiome
Interventions
Lactobacillus rhamnosus GG, Lactobacillus rhamnosus GG Placebo
Dietary Supplement
Lead sponsor
Duke University
Other
Eligibility
1 Year and older
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 14, 2026, 1:23 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 14, 2026, 1:23 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of RSLV-132 in Subjects With Long COVID

NCT04944121
View directory record Official record
Conditions
Post-acute Corona Virus 19 (COVID-19) (Long COVID)
Interventions
RSLV-132, Sodium Chloride 0.9%
Drug
Lead sponsor
Resolve Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Mobile, Alabama • Coral Gables, Florida • Pompano Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 14, 2026, 1:23 PM EDT
Terminated Phase 2 Interventional

An Outpatient Study Investigating Non-prescription Treatments for COVID-19

NCT04621149
View directory record Official record
Conditions
COVID-19
Interventions
chlorine dioxide, zinc acetate, Famotidine, placebo, lactoferrin, green tea extract
Other · Dietary Supplement · Drug
Lead sponsor
Profact, Inc.
Other
Eligibility
20 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 30, 2022 · Synced Oct 14, 2026, 1:23 PM EDT
Terminated Phase 3 Interventional Results available

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)

NCT04343248
View directory record Official record
Conditions
COVID-19, Viral Respiratory Illnesses
Interventions
Nitazoxanide, Placebo, Vitamin Super B-Complex
Drug · Dietary Supplement
Lead sponsor
Romark Laboratories L.C.
Industry
Eligibility
55 Years to 120 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Kissimmee, Florida • Acworth, Georgia • Lake Charles, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Oct 14, 2026, 1:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CareSuperb COVID-19 Antigen Test Usability

NCT05629455
View directory record Official record
Conditions
COVID-19
Interventions
CareSuperb COVID-19 Antigen Home Test Kit
Device
Lead sponsor
AccessBio, Inc.
Other
Eligibility
2 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 14, 2026, 1:23 PM EDT
Completed Phase 2 Interventional

A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia

NCT05672355
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, COVID-19 Infection
Interventions
Biospecimen Collection, mRNA COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 14, 2026, 1:23 PM EDT
Completed No phase listed Observational

Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus

NCT05867017
View directory record Official record
Conditions
COVID-19, Diabete Mellitus
Interventions
Measure of physiologic parameters
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 14, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19.

NCT04348435
View directory record Official record
Conditions
COVID-19
Interventions
HB-adMSCs, Placebos
Biological · Other
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 14, 2026, 1:23 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Physical Rehabilitation of COVID-19 Survivors by Heat Therapy

NCT04673318
View directory record Official record
Conditions
Covid19, Physical Disability
Interventions
heat therapy, exercise training
Behavioral
Lead sponsor
University of Massachusetts, Amherst
Other
Eligibility
55 Years to 85 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Amherst, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 14, 2026, 1:23 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

NCT06679140
View directory record Official record
Conditions
COVID-19 SARS-CoV-2 Infection
Interventions
ibuzatrelvir, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
2,330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
87
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Bakersfield, California + 64 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 1:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic

NCT04368260
View directory record Official record
Conditions
COVID19
Interventions
Control swab, Prototype swab
Device
Lead sponsor
University of Virginia
Other
Eligibility
0 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 14, 2026, 1:23 PM EDT
Completed Phase 2Phase 3 Interventional Results available

ACTIV-2: A Study for Outpatients With COVID-19

NCT04518410
View directory record Official record
Conditions
Coronavirus, Covid19
Interventions
bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4,044 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
207
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 14, 2026, 1:23 PM EDT
Terminated No phase listed Observational

A Wearable, Battery-free Screening System for SARS-CoV-2, the Virus Causing COVID-19 Infection

NCT04807075
View directory record Official record
Conditions
Covid19
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 14, 2026, 1:23 PM EDT
Completed No phase listed Observational

Insulin Regulation and Severity of Severe Acute Respiratory Syndrome COVID-19 Infection

NCT05897528
View directory record Official record
Conditions
COVID-19, Diabetes Mellitus, COVID-19 Pneumonia, COVID-19 Respiratory Infection
Interventions
No Intervention
Other
Lead sponsor
Arrowhead Regional Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
589 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Colton, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 14, 2026, 1:23 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19

NCT04424901
View directory record Official record
Conditions
COVID-19 Pneumonia, Vascular Complications
Interventions
Placebo, Dipyridamole Tablets
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 14, 2026, 1:23 PM EDT
No Longer Available No phase listed Expanded access

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection

NCT04366830
View directory record Official record
Conditions
Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19
Interventions
Remestemcel-L
Drug
Lead sponsor
Mesoblast International Sàrl
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 14, 2026, 1:23 PM EDT
Terminated Phase 3 Interventional Results available

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19

NCT04425629
View directory record Official record
Conditions
COVID-19
Interventions
casirivimab+imdevimab combination therapy
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
10,078 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
102
States / cities
Mesa, Arizona • Tucson, Arizona • Canoga Park, California + 71 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 14, 2026, 1:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness

NCT05175690
View directory record Official record
Conditions
COVID19
Interventions
Diagnostic Software as Medical Device
Diagnostic Test
Lead sponsor
AudibleHealth AI, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 14, 2026, 1:23 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Positron Emission Tomography (PET) Imaging of Thrombosis

NCT03830320
View directory record Official record
Conditions
Atrial Fibrillation, COVID-19, Cancer, Thrombosis
Interventions
[64Cu]FBP8, PET/MR, Blood Collection, Electrocardiogram
Drug · Device · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 14, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years

NCT04895982
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID19
Interventions
BNT162b2
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
2 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Jefferson, Louisiana • Kenner, Louisiana • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 14, 2026, 1:23 PM EDT
Active, not recruiting Phase 2 Interventional

The Long COVID Treatment Trial

NCT07128082
View directory record Official record
Conditions
Long COVID
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 14, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Results available

TD-0903 for ALI Associated With COVID-19

NCT04402866
View directory record Official record
Conditions
Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19
Interventions
TD-0903, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Duarte, California • Denver, Colorado • Sebring, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 14, 2026, 1:23 PM EDT